Ipsen – Consolidated Financial Statements – 2022

Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance